

G W Kershaw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9174788/publications.pdf>

Version: 2024-02-01

25
papers

504
citations

686830

13
h-index

676716

22
g-index

25
all docs

25
docs citations

25
times ranked

432
citing authors

#	ARTICLE	IF	CITATIONS
1	Mixing Tests: Diagnostic Aides in the Investigation of Prolonged Prothrombin Times and Activated Partial Thromboplastin Times. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 283-290.	1.5	63
2	How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 022-035.	1.5	63
3	Laboratory Identification of Factor Inhibitors: The Perspective of a Large Tertiary Hemophilia Center. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 760-768.	1.5	46
4	Laboratory Identification of Lupus Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 375-384.	1.5	46
5	Laboratory identification of factor inhibitors: an update. <i>Pathology</i> , 2012, 44, 293-302.	0.3	42
6	Recombinant to modified factor VIII and factor IX – chromogenic and one-stage assays issues. <i>Haemophilia</i> , 2016, 22, 72-77.	1.0	38
7	Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study. <i>Scientific Reports</i> , 2021, 11, 7975.	1.6	31
8	The Effects of Haemodilution with Albumin on Coagulation in Vitro as Assessed by Rotational Thromboelastometry. <i>Anaesthesia and Intensive Care</i> , 2015, 43, 187-192.	0.2	20
9	Problems and Solutions in Laboratory Testing for Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 135-135.	1.5	18
10	Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 975-988.	1.9	17
11	Detection and Measurement of Factor Inhibitors. <i>Methods in Molecular Biology</i> , 2017, 1646, 295-304.	0.4	15
12	Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants. <i>Methods in Molecular Biology</i> , 2017, 1646, 75-83.	0.4	14
13	Evaluation of chromogenic factor IX assays by automated protocols. <i>Haemophilia</i> , 2018, 24, 492-501.	1.0	14
14	Performance and Interpretation of Mixing Tests in Coagulation. <i>Methods in Molecular Biology</i> , 2017, 1646, 85-90.	0.4	12
15	Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors. <i>Thrombosis Research</i> , 2013, 132, 735-741.	0.8	9
16	The Effects of Haemodilution with Hydroxyethyl Starch 130/0.4 Solution on Coagulation as Assessed by Thromboelastography and Platelet Receptor Function Studies in Vitro. <i>Anaesthesia and Intensive Care</i> , 2015, 43, 734-739.	0.2	9
17	A multi-laboratory assessment of lupus anticoagulant assays performed on the ACL TOP 50 family for harmonized testing in a large laboratory network. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 654-665.	0.7	9
18	Harmonizing platelet function analyzer testing and reporting in a large laboratory network. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 934-944.	0.7	9

#	ARTICLE	IF	CITATIONS
19	Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high-dose bypassing agents in the HAVEN 1 study. <i>Haemophilia</i> , 2020, 26, e340-e342.	1.0	8
20	Performance of factor IX extended half-life product measurements in external quality control assessment programs. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1874-1883.	1.9	8
21	Evaluation of the technicon H-1 hematology analyser. <i>Pathology</i> , 1987, 19, 305-309.	0.3	4
22	Laboratory monitoring issues in recombinant porcine FVIII replacement in acquired haemophilia A. <i>Haemophilia</i> , 2018, 24, e70-e74.	1.0	3
23	A diagnosis of von Willebrand disease despite normal test results for factor VIII and von Willebrand factor antigen and activity. <i>American Journal of Hematology</i> , 2019, 94, 1425-1432.	2.0	3
24	Australian comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein (Eloctate®). <i>Haemophilia</i> , 2020, 26, e226-e229.	1.0	2
25	Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement. <i>Pathology</i> , 2022, , .	0.3	1